Double Stimulation Followed by a Fresh Embryo Transfer (DUO_STIM_FRESH)
Infertility
About this trial
This is an interventional treatment trial for Infertility
Eligibility Criteria
Inclusion Criteria:
- Poor prognosis patients according to the POSEIDON group 3 & 4 (based on AMH)
- AMH <1.2
- age <40 years old
- BMI >18 and <35 kg/m2
- Body weight >50kg (in women <36 years old body weight >60kg)
Exclusion Criteria:
- Maternal age > 40 years
- History of untreated autoimmune, endocrine or metabolic disorders
- Previous ovarian cystectomy or oophorectomy
- Body weight <50kg (and body weight <60kg in women <36 years old)
Sites / Locations
- Hospital Universitario Quiron Dexeus
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Double Stimulation (Elonva+rFSH) in luteal /follicular phase
Conventional Stimulation (Elonva+rFSH) in follicular phase
A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp & Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach. A second stimulation will start on day 2 of bleeding after the first oocyte retrieval. This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)
A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG